eng Oriental Scientific Publishing Company Biosciences Biotechnology Research Asia 0973-1245 2025-12-30 22 4 1368 1384 10.13005/bbra/3448 56860 article Jyoti Bhatol 1 Sangeeta Dwivedi 1 Vikas Kumar Jain 1 Neha Sisodiya 1 Gajanan Darwhekar 1 Department of Pharmacology, Acropolis Institute of Pharmaceutical Education and Research, Indore, M.P., India. Candida albicans is the most common fungal pathogen responsible for both invasive and mucosal infections. The primary antifungal drug classes used against C. albicans remain azoles, echinocandins, and polyenes. However, resistance to these agents has been steadily increasing, thereby limiting their clinical effectiveness. To overcome these challenges, several novel antifungal agents have been developed and recently approved. This review aims to highlight recent developments in antifungal drug discovery and resistance mechanisms associated with Candida albicans. A comprehensive literature review was conducted using electronic databases including PubMed, ScienceDirect, and Scopus. Rezafungin, a long-acting echinocandin, offers potent fungicidal activity with convenient once-weekly dosing. Ibrexafungerp, the first orally available glucan synthase inhibitor, retains efficacy against echinocandin-resistant isolates. Fosmanogepix, a prodrug targeting the Gwt1 enzyme, disrupts mannoprotein anchoring and compromises fungal cell wall integrity. Oteconazole, a highly selective tetrazole that inhibits fungal CYP51, demonstrates enhanced effectiveness against azole-resistant strains and recurrent vulvovaginal candidiasis. In conclusion, these emerging antifungals expand the antifungal arsenal, addressing limitations of current treatments while offering improved efficacy, safety, and options against drug-resistant Candida albicans infections. https://www.biotech-asia.org/vol22no4/exploring-new-antifungal-agents-for-the-treatment-of-candida-infections-in-the-era-of-resistance/ Antifungal Resistance; Biofilm; Candida albicans; Fungal; Infection; Novel Antifungal Agents